C18 Ganglioside GD3-d3 is intended for use as an internal standard in the quantification of ganglioside GD3 by GC- or LC-MS. Ganglioside GD3 is synthesized by the addition of two sialic acid residues to lactosylceramide and can serve as a precursor to the formation of more complex gangliosides by the action of glycosyl- and sialyltransferases. With roles in cell proliferation and differentiation, its expression increases during development and in pathological conditions such as cancer.1 Furthermore, the intracellular accumulation of ganglioside GD3 can contribute to mitochondrial damage, a crucial event during apoptosis.2 Ganglioside GD3 has become a target for therapeutic approaches to prevent malignant properties of tumor cells like melanoma.1,3 [Matreya, LLC. Catalog No. 2054]
1.Hamamura, K., Furukawa, K., Hayashi, T., et al.Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cellsProc. Natl. Acad. Sci. USA102(31)11041-11046(2005) 2.De Maria, R., Lenti, L., Malisan, F., et al.Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosisScience277(5332)1652-1655(1997) 3.Nicoll, G., Avril, T., Lock, K., et al.Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanismsEur. J. Immunol.33(6)1642-1648(2003)